A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects
NCT ID: NCT06175949
Last Updated: 2023-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
70 participants
INTERVENTIONAL
2023-12-31
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HRS-7085
HRS-7085 Tablets
HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
HRS-7085 simulant
HRS-7085 simulant
PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HRS-7085 Tablets
HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
HRS-7085 simulant
PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body Mass Index (BMI = weight/height\^2) during screening: 19 ≤ BMI \< 28 kg/m\^2; male weight ≥ 50.0 kg and \< 90.0 kg, female weight ≥ 45.0 kg and \< 90.0 kg.
3. Healthy subjects with physical examination, vital signs, and laboratory test results (including complete blood count, urinalysis, blood biochemistry, coagulation function, thyroid function), chest X-ray, 12-lead electrocardiogram, abdominal ultrasound, judged by the investigator as normal or clinically insignificant abnormalities during screening.
4. Female subjects of reproductive potential and male subjects with female partners of reproductive potential must have no plans for reproduction, sperm/egg donation for at least 3 months after the last dose and voluntarily agree to use effective contraception. Serum pregnancy test for female subjects must be negative and not in lactation.
5. Obtain informed consent before any trial-related activities begin, fully understand the purpose and significance of this trial, and be willing to comply with the trial protocol.
Exclusion Criteria
2. Within the past 6 months prior to screening or dosing, individuals with a history of severe infections (such as bloodstream infections, central nervous system infections, abdominal infections, etc.), severe trauma, or major surgeries (excluding appendectomy); those planning to undergo surgery during the trial.
3. Within the past month prior to screening or dosing, individuals with a history of infections (viral, bacterial, fungal, parasitic) requiring systemic antimicrobial therapy.
4. Individuals experiencing frequent headaches, nausea, and/or vomiting with a frequency of ≥3 times per month.
5. Individuals with allergic tendencies, such as a history of asthma, atopic dermatitis, chronic urticaria, allergic rhinitis, or any known allergies to drugs or foods.
6. Within the past month prior to screening or dosing, individuals who donated blood or experienced blood loss ≥200 mL, or within the past 3 months prior to dosing, individuals who donated blood or experienced blood loss ≥400 mL.
7. As determined by the study physician, individuals with any physiological or psychological condition that may increase trial risks, affect subject compliance with the protocol, or interfere with subject completion of the trial.
8. Individuals with a smoking history within the past 3 months prior to screening (average daily smoking \>5 cigarettes) or those unable to abstain from any tobacco products during the trial.
9. Within the past month prior to screening, individuals with an average daily alcohol intake exceeding 7 g for females (equivalent to approximately 200 mL of beer, 70 mL of wine, or 22 mL of spirits) or exceeding 14 g for males (equivalent to approximately 400 mL of beer, 140 mL of wine, or 45 mL of spirits); or individuals with a positive alcohol test at screening or those unable to abstain from alcohol during the trial.
10. Individuals who consumed any grapefruit-containing foods or beverages within 7 days prior to taking the study drug, or those who consumed caffeine-containing foods or beverages within 2 days prior to taking the study drug.
11. Individuals with special dietary requirements who cannot adhere to a standardized diet.
12. Individuals with a history of drug abuse or substance misuse, or those with a positive urine drug screen at screening.
13. Individuals with positive results in infectious disease screening tests (HBsAg, anti-HCV Ab, anti-TP Ab, anti-HIV Ab) at screening.
14. Individuals with alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin (TBIL) levels ≥1.5 times the upper limit of normal (ULN) at screening.
15. Within 2 weeks prior to screening or dosing, individuals who used any prescription medications, over-the-counter medications, or herbal supplements; or individuals within 5 half-lives of a drug (whichever is longer) at screening or planning to use non-study investigational drug during the trial.
16. Within the past 3 months prior to screening, individuals who participated in any other clinical trial (excluding those who failed screening) or those still within 5 half-lives of a drug (whichever is longer) at screening.
17. Within the past 3 months prior to screening, individuals who received a live vaccine or attenuated live vaccine, or those planning to receive any vaccines during the trial.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Suncadia Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRS-7085-101
Identifier Type: -
Identifier Source: org_study_id